In summary, our data demonstrate that the PK and pharmacodynamics of drugs with a high level of CYP interaction, such as clopidogrel and pantoprazole, may be significantly altered in patients with chronic kidney disease undergoing hemodialysis. This evidence concerns the gene PPIG and chronic kidney disease.